首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Serum amyloid A protein (SAA) in colorectal carcinoma.
【24h】

Serum amyloid A protein (SAA) in colorectal carcinoma.

机译:大肠癌中的血清淀粉样蛋白A(SAA)。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The changes in serum levels of serum amyloid A protein were studied in 67 patients suffering from colorectal carcinoma and compared to three other major acute phase proteins: C-reactive protein, alpha1-antichymotrypsin and alpha1-acid glycoprotein. Although the presence of colorectal carcinoma caused an increase in serum levels of all the acute phase reactants studied, serum amyloid A protein showed the most powerful reaction in pre-operative disease stage, with the mean value of 330 mg/l (range 7-2506 mg/l) as compared to the normal values of <1.2 mg/l obtained in 30 healthy adults. The mean serum amyloid A protein concentration increased to 487 mg/l after surgery, declining during the post-operative clinical course until the sixth chemotherapy cycle (from 167 mg/l to 64 mg/l), but never returned to the normal range. In the later chemotherapy cycles, mean serum amyloid A protein increased to 163 mg/l, probably as a result of the disease relapse. According to the statistical relations among exact confidence intervals for proportions, serum amyloid A protein showed the best specificity for colorectal carcinoma of all the acute phase proteins studied (83-100%) and also a sensitivity of 100%. We concluded that serum amyloid A protein seems to be a reliable parameter, which could be recommended for clinical routine as a non-specific tumour marker for colorectal carcinoma.
机译:在67名患有大肠癌的患者中研究了血清淀粉样蛋白A蛋白的水平变化,并将其与其他三种主要的急性期蛋白进行了比较:C反应蛋白,α1-抗胰凝乳蛋白酶和α1酸性糖蛋白。尽管大肠癌的存在导致所有研究的急性期反应物的血清水平增加,但血清淀粉样蛋白A蛋白在术前疾病阶段表现出最强的反应,平均值为330 mg / l(范围7-2506)毫克/升)与30名健康成年人的正常值<1.2毫克/升相比。手术后,血清淀粉样蛋白A的平均浓度增加到487 mg / l,在术后临床过程中一直下降到第六个化疗周期(从167 mg / l降至64 mg / l),但从未恢复到正常范围。在随后的化疗周期中,血清淀粉样蛋白A的平均含量增加到163 mg / l,这可能是疾病复发的结果。根据各比例的确切置信区间之间的统计关系,血清淀粉样蛋白A蛋白对所有研究的急性期蛋白(83-100%)显示出对结直肠癌的最佳特异性,敏感性为100%。我们得出的结论是,血清淀粉样蛋白A蛋白似乎是一个可靠的参数,可以建议将其作为大肠癌的非特异性肿瘤标志物用于临床常规。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号